Introduction
============

In recent years, type 2 diabetes mellitus (T2DM) has emerged as a global epidemic, which is predicted to worsen in the coming decades, particularly in developing countries. Rapid urbanization, changes in nutrition, dietary patterns, sedentary habits, and obesity have all contributed to the progression of the epidemic in the Middle East.[@b1-vhrm-11-149] The current prevalence of diabetes in the Middle East and North Africa (MENA) region is estimated to be 9.2%, which is equivalent to 34.6 million people with diabetes. This figure is expected to double by 2035 to 67.9 million.[@b2-vhrm-11-149] Nearly half of the people with T2DM remain undiagnosed, and in those who are diagnosed, glycemic control is suboptimal, which potentially increases the risk of diabetes complications and results in poor health outcomes.[@b2-vhrm-11-149] A systematic review of a subset of countries in the Gulf region, which summarized the findings of 27 studies, reported that \<50% of people with diabetes reached their targets for the management of risk factors such as glycemic control, hypertension, and dyslipi-demia,[@b3-vhrm-11-149] suggesting the need for implementation of strategies for prevention, early detection, and consistent management of T2DM. This further underscores the need for developing countries to review, update, and implement new national diabetes programs that will help access the effectiveness of newer therapies and their cost-effectiveness.

Current treatment guidelines for management of T2DM recommend a patient-centered approach taking into account factors such as effectiveness, tolerability, long-term safety, cost, and patient preferences when choosing antihyperglycemic agents.[@b4-vhrm-11-149] T2DM is a chronic progressive disease, so often requires treatment intensification with multiple oral antidiabetic drugs (OADs) that have complementary mechanisms of action to maintain glycemic control and prevent long-term complications.[@b4-vhrm-11-149] However, there is limited information available on the effectiveness of newer therapeutic alternatives for diabetes, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, in the Middle Eastern population, possibly due to under-representation of patients from this region in large randomized global studies. Thus, real-life data are needed to understand the impact of differences in environmental, genetic, and physical factors and clinical practice in the overall response to newer therapies and further management of T2DM in the Middle Eastern population. Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control by increasing α-cell and β-cell responsiveness to glucose and has been shown to be weight neutral with no additional risk for hypoglycemia.[@b5-vhrm-11-149]--[@b7-vhrm-11-149] The efficacy and safety of vildagliptin both as monotherapy and in combination with other OADs has been demonstrated in randomized clinical trials.[@b7-vhrm-11-149]--[@b10-vhrm-11-149]

We performed a post hoc analysis of the EDGE (Effectiveness of Diabetes control with vildaGliptin and vildagliptin/mEtformin) study to evaluate the effectiveness and tolerability of add-on vildagliptin compared with any other OADs added to monotherapy in real-life clinical practice, which provided us with an opportunity to look into the regional perspectives of real-life management of T2DM.[@b11-vhrm-11-149] Here we present the results from the EDGE study for participants from seven countries in the Middle East (Jordan, Palestine, Oman, Bahrain, Kuwait, Lebanon, and the United Arab Emirates). Three of the seven countries included in the present analysis (Bahrain, Kuwait, and the United Arab Emirates) are among the top 15 countries in the world with respect to national prevalence of diabetes.[@b12-vhrm-11-149]

Materials and methods
=====================

Study design and patient population
-----------------------------------

The EDGE study enrolled 45,868 people with T2DM across 27 countries from Europe, East Asia, India, Latin America, and the Middle East. Details of the study population and design are reported elsewhere.[@b11-vhrm-11-149] In brief, people with T2DM aged ≥18 years, taking OAD monotherapy, and prescribed a new add-on OAD by the physician at their discretion based on patient need were enrolled in the study. Participants were assigned to one of two cohorts ([Figure 1](#f1-vhrm-11-149){ref-type="fig"}) to receive vildagliptin or comparator OADs (metformin, sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors) as add-on to monotherapy. People who were prescribed DPP-4 inhibitors other than vildagliptin or glucagon-like peptide-1 mimetics/analogs were excluded. All participants provided informed consent before enrolling in the study. To avoid physician bias for a particular choice of antihyperglycemic agent, patients were enrolled in the study only after they had received the prescription for an OAD. The term "index therapy" is used to represent the combination treatment initiated at enrollment. For any index therapy, a fixed-dose combination was allowed, if available.

Study assessments
-----------------

The primary endpoint was the proportion of participants responding to treatment with an HbA~1c~ reduction \>0.3% from baseline to study endpoint with no tolerability findings such as peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event, or weight gain ≥5%. One of the secondary endpoints was the responder rate, measured as the proportion of participants achieving target HbA~1c~ \<7.0% at the end of study without hypoglycemia or weight gain ≥3% in participants with baseline HbA~1c~ ≥7%. The change in HbA~1c~ from baseline to study endpoint (analysis not prespecified in the protocol) and the number of hypoglycemic events were also evaluated in this post hoc analysis. Hypoglycemia was defined as symptoms suggestive of hypoglycemia including mild and severe events that resolved promptly after administration of an oral carbohydrate.

Statistical analysis
--------------------

Descriptive statistics were used for these regional post hoc analyses. Baseline demographics and safety data are reported for the intent-to-treat population that comprised participants newly receiving dual therapy including vildagliptin or other OADs, except incretin-based therapies, added to prior monotherapy. The analyses for the primary and secondary composite endpoints utilized the per protocol population, which was a subset of the intent-to-treat population without protocol deviations. Data were censored if participants changed their index therapy. A binary logistic regression model was used to calculate the odds ratios (ORs) with 95% confidence intervals (CIs) for the probability of success in achieving the primary and secondary endpoints. The OR expresses odds in favor of success with vildagliptin combinations relative to odds in favor of success with comparator OADs. Participants whose outcomes could not be categorized as a success or failure (eg, due to missing HbA~1c~ or body weight data at the 12-month endpoint) were considered non-evaluable and not included in the calculation of the OR. Only unadjusted ORs are reported for the primary and secondary endpoints. Change in HbA~1c~ was adjusted with respect to baseline value by using the analysis of covariance model. The change in HbA~1c~ from baseline to study endpoint was calculated for the intent-to-treat population; however, the statistical significance between cohorts was not assessed because the analysis was not prespecified in the protocol. The protocol for the EDGE study was approved by all local independent review boards or ethics committees.

Results
=======

Of the 4,780 participants enrolled in the Middle East, 2,513 participants were assigned to the vildagliptin cohort and 2,267 participants were assigned to the comparator cohort ([Table 1](#t1-vhrm-11-149){ref-type="table"}). Despite the non-randomized nature of the study, the cohorts were well balanced for demographic and baseline characteristics. Overall, on average, the participants were 52 years of age, with a body mass index of 29.4 kg/m^2^, HbA~1c~ 8.5%, and a T2DM duration of 4.2 years at monotherapy failure ([Table 2](#t2-vhrm-11-149){ref-type="table"}). Although the baseline demographics were well balanced between the two cohorts, there were small but statistically significant differences observed between age, body mass index, and duration of diabetes. Participants in the comparator cohort were on average 1.4 years older (*P*=0.000) and had a longer duration of T2DM by 0.4 years (*P*=0.000) when compared with the vildagliptin cohort. [Table 3](#t3-vhrm-11-149){ref-type="table"} reports index therapies in the intent-to-treat population for both cohorts. At study entry, most participants (\~86%) were receiving metformin monotherapy, followed by sulfonylureas (\~11%), thiazolidinediones (\~2.0%), glinides and alpha-glucosidase inhibitors (1.0% each).

Efficacy
--------

The primary endpoint was reached in 76.1% of participants in the vildagliptin cohort versus 61.6% of participants in the comparator OAD cohort, with an unadjusted OR of 1.98 (95% CI 1.75--2.25; *P*\<0.0001) in favor of vildagliptin. Likewise, the responder rate for the secondary endpoint (achieving HbA~1c~ \<7.0% without hypoglycemia or weight gain ≥3% in those patients with baseline HbA~1c~ ≥7%) was higher in the vildagliptin cohort compared with the comparator OAD cohort (54.8% versus 29.9%, respectively), resulting in an unadjusted OR of 2.8 (95% CI 2.5--3.2; *P*\<0.0001) in favor of vildagliptin ([Figure 2A](#f2-vhrm-11-149){ref-type="fig"}). After 12 months of treatment, mean HbA~1c~ decreased from baseline in both cohorts (−1.7% with vildagliptin versus −1.4% with comparators), with a between-group difference of −0.3% ([Figure 2B](#f2-vhrm-11-149){ref-type="fig"}).

Safety
------

Overall, 87 patients (3.5%) in the vildagliptin cohort and 135 patients (6.0%) in the comparator cohort reported adverse events. The occurrence of serious adverse events was low in both the cohorts; two patients (0.1%) in each cohort reported serious adverse events, and none of them were considered to be related to the study drug. No death occurred in either cohort. The incidence of hypoglycemia was low at 0.4% and 2.3% in the vildagliptin and comparator OAD cohorts, respectively.

Discussion
==========

The increasing prevalence of T2DM in the Middle East, especially among the younger age groups, is worrying; half of all deaths from diabetes in the MENA region have been reported to occur in people aged \<60 years.[@b12-vhrm-11-149] Further, there are limited data on glycemic control and management of T2DM for newer therapies in the region. Thus, more real-life studies that provide an evidence base for the long-term management of T2DM are warranted. The present post hoc analysis of the EDGE study in the Middle East regarding the effectiveness and tolerability of vildagliptin as add-on to another OAD compared with all other OAD combinations in people with T2DM will complement the data from randomized controlled trials. The baseline HbA~1c~ in the present post hoc analysis in the Middle East was high (8.5%) confirming the expected high prevalence of inadequate glycemic control in this region, despite continuous efforts to raise awareness of adequate glycemic control in order to prevent the complications of diabetes.[@b12-vhrm-11-149] The mean baseline HbA~1c~ in the Middle East was higher than the global average in the EDGE study (8.2%); however, it is similar to the mean baseline HbA~1c~ observed in Latin America (8.5%) and India (8.6%).[@b13-vhrm-11-149],[@b14-vhrm-11-149] Changes in dietary habits, physical inactivity, sedentary lifestyle, urbanization, smoking, educational level, and lack of awareness about the disease and its long-term complications have been reported as factors contributing to the suboptimal glycemic control in this region.[@b15-vhrm-11-149],[@b16-vhrm-11-149] After one year of treatment, more participants in the vildagliptin cohort achieved the primary endpoint of an HbA1c decrease .0.3%, with no associated tolerability findings; than in the comparator OAD cohort. The vildagliptin cohort also showed a greater responder rate (proportion of participants achieving HbA~1c~ \<7.0% without hypoglycemia or weight gain ≥3% in participants with baseline HbA~1c~ ≥7%) than the comparator OAD cohort. Tolerability factors such as body weight, hypoglycemia, and gastrointestinal events have driven the non-response to treatment in the comparator cohort (data not shown), which could be correlated with the maximum number of patients (\~80%) taking sulfonylureas. These findings are similar to the proportion of patients achieving primary and secondary endpoints with vildagliptin in other regions/countries like Latin America, India, and the 12 participating European countries in the study (including Germany), despite the diverse representation of populations from these regions.[@b13-vhrm-11-149],[@b14-vhrm-11-149],[@b17-vhrm-11-149],[@b18-vhrm-11-149] The HbA~1c~ reduction in the present post hoc analysis was numerically higher in the vildagliptin cohort than in the comparator OAD cohort. The proportion of participants reaching the primary and secondary endpoints, as well as the HbA~1c~ reduction observed in the present study, were slightly higher than the findings from the overall EDGE study.[@b11-vhrm-11-149] Indeed, recently published data suggest that the efficacy of comparators, such as sulfonylureas, might be diminished in a real-life setting versus randomized controlled trials, indicating that the maximal doses of comparator OADs, sulfonylureas in particular, were not always utilized, due at least in part to concern about potential side effects.[@b19-vhrm-11-149]

The high HbA~1c~ reductions seen in the present analysis might be due to the high baseline HbA~1c~ of participants in the Middle East region. Shorter duration of T2DM and young age of participants have been associated with better glycemic control in previous studies;[@b20-vhrm-11-149],[@b21-vhrm-11-149] this may also partly explain the higher responder rate in the present analysis.

Overall, the present safety/tolerability findings are in line with data from the clinical studies of vildagliptin showing no new safety signals, this includes no new cardiovascular, cere brovascular, pancreatic, hepatic, immune system, or skin disorders.[@b22-vhrm-11-149],[@b23-vhrm-11-149] The incidence of hypoglycemia was low in the vildagliptin cohort versus the comparator OAD cohort, which is consistent with the results of an earlier study showing a similar reduced frequency of hypoglycemia with vildagliptin compared with sulfonylureas in a real-life setting.[@b24-vhrm-11-149] Further, these results are consistent with those of an observational study conducted in Asia and the Middle East in patients fasting during Ramadan which showed a low incidence of hypoglycemia with vildagliptin versus sulfonylureas.[@b25-vhrm-11-149],[@b26-vhrm-11-149] The low risk of hypoglycemia seen with vildagliptin is also of particular interest in the Middle East region, which has a largely Muslim population that fasts during the holy month of Ramadan. There is a high likelihood that a significant patient population from the Middle East region participating in the 12-month EDGE study might have fasted safely during Ramadan with no additional risk of hypoglycemia. The low incidence of hypoglycemia observed might be explained by vildagliptin's effect of increasing glucose-dependent insulinotropic polypeptide levels between meals and overnight, when hypoglycemia is most likely to occur, thereby increasing glucagon levels in hypoglycemia.[@b10-vhrm-11-149]

Our study has certain limitations. Due to its open-label design, physicians could have selected any drug based on their clinical judgment, resulting in an imbalance in the treatment arms, favoring the newly introduced alternative agent, vildagliptin, in the overall EDGE study. However, in the present analysis, both cohorts seem to be balanced despite the open-label design. Further, in controlled clinical trial settings, reporting of adverse events is done in a systematic manner on dedicated forms, but in the present observational study was done based on a voluntary reporting system, which might have resulted in under-reporting of events. Despite its limitations, the EDGE study mapped real-life clinical practice in the Middle East with lifestyle interventions followed by metformin being prescribed as first-line therapy followed by treatment intensification if patients were not at goal, so the findings are reflective of real-life T2DM management.

In conclusion, the results of this post hoc analysis of real-life clinical practice in the Middle East demonstrate that, in people with T2DM in whom second-line oral glucose-lowering therapy was initiated, vildagliptin resulted in lowering HbA~1c~ to \<7.0% without weight gain, hypoglycemia, or peripheral edema, despite the delayed intensification of treatment with second-line OAD as suggested by a high baseline HbA~1c~ at time of enrollment. Vildagliptin has a good safety profile and was generally well tolerated.
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![Study design.\
**Notes:** \*Vildagliptin cohort includes people with T2DM newly initiating vildagliptin as add-on dual OAD therapy, or newly initiating vildagliptin-metformin (fixed dose) from non-vildagliptin monotherapy; \*\*comparator OAD cohort includes people with T2DM newly initiating dual OAD therapy with antidiabetic therapies other than vildagliptin (defined as sulfonylureas, metformin, thiazolidinediones, metiglinides, or α-glucosidase inhibitors as add-on dual therapy) except as add-on to vildagliptin, other dipeptidyl peptidase-4 inhibitors, or glucagon-like peptide-1 mimetics/analogs.\
**Abbreviations:** AEs, adverse events; OADs, oral anti-diabetic drugs; SAEs, serious adverse events; T2DM, type 2 diabetes mellitus.](vhrm-11-149Fig1){#f1-vhrm-11-149}

![(**A**) Proportion of participants achieving study endpoints in per protocol population. (**B**) Mean (± standard error) change in HbA~1c~ from baseline to study endpoint in intent-to-treat population using an adjusted analysis of covariance method. The primary endpoint was the proportion of patients experiencing an HbA~1c~ decrease of \>0.3% without hypoglycemia, weight gain, peripheral edema, or gastrointestinal side effects. \**P*\<0.0001 for unadjusted odds ratio of 1.98 (95% confidence interval 1.75--2.25). The secondary endpoint was the proportion of patients reaching HbA~1c~ \<7% with no hypoglycemic events and weight gain. \**P*\<0.0001 for unadjusted odds ratio of 2.8 (95% confidence interval 2.5--3.2).\
**Abbreviations:** HbA~1c~, glycated hemoglobin; OADs, oral antidiabetic drugs.](vhrm-11-149Fig2){#f2-vhrm-11-149}

###### 

Patient population and flow

  Enrolled[\*](#tfn1-vhrm-11-149){ref-type="table-fn"} (n=4,780)                         Vildagliptin cohort   Comparator cohort
  -------------------------------------------------------------------------------------- --------------------- -------------------
  Assigned                                                                               2,513                 2,267
  No adequate source documentation at site; lack of quality and accuracy of data entry   0                     1
  Intent to treat[\*\*](#tfn2-vhrm-11-149){ref-type="table-fn"}                          2,513                 2,266
  Completed                                                                              2,390                 2,137
  Discontinued                                                                           123                   129
  Per protocol[\*\*\*](#tfn3-vhrm-11-149){ref-type="table-fn"}                           2,503                 2,264

**Notes:**

Enrolled population includes all patients who gave documented informed consent;

intent-to-treat population is a subset of the enrolled population and includes all patients who were assigned to new treatment at study start;

per protocol population is a subset of the intent-to-treat population which completed the study without any major protocol deviation. It was used for analysis of effectiveness endpoints.

###### 

Demographic and patient baseline characteristics (intent-to-treat population)

  Characteristic             Vildagliptin   Comparator     Total          *P*-value
  -------------------------- -------------- -------------- -------------- -----------
  Age (years)                51.4±10.10     52.8±10.33     52.1±10.23     0.000
  Sex, male                  1,599 (63.6)   1,343 (59.3)   2,942 (61.6)   0.002
  BMI (kg/m^2^)              29.7±4.8       29.1±4.6       29.4±4.7       0.000
  HbA~1c~ (%)                8.5±1.2        8.5±1.3        8.5±1.3        0.045
  Duration of T2DM (years)   4.0±4.0        4.4±4.0        4.2±4.0        0.000

**Abbreviations:** BMI, body mass index; HbA~1c~, glycated hemoglobin; SD, standard deviation; T2DM, type 2 diabetes mellitus.

###### 

Index medication (intent-to-treat population)

  Vildagliptin cohort (n =2,513)[\*](#tfn5-vhrm-11-149){ref-type="table-fn"}   Comparator cohort (n =2,266)[\*](#tfn5-vhrm-11-149){ref-type="table-fn"}                       
  ---------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------- --------------
  Metformin-vildagliptin                                                       2,028 (80.8)                                                               Metformin-SU        1,686 (74.5)
  SU-vildagliptin                                                              399 (15.9)                                                                 Metformin-TZD       328 (14.5)
  TZD-vildagliptin                                                             50 (2.0)                                                                   SU-TZD              128 (5.7)
  Glinide-vildagliptin                                                         26 (1.0)                                                                   Glinide-metformin   68 (3.0)
  AGI-vildagliptin                                                             7 (0.3)                                                                    AGI-metformin       27 (1.2)
  AGI-SU                                                                       12 (0.5)                                                                                       
  Glinide-SU                                                                   6 (0.3)                                                                                        
  AGI-TZD                                                                      4 (0.2)                                                                                        
  Glinide-TZD                                                                  4 (0.2)                                                                                        
  AGI-glinide                                                                  1 (0.04)                                                                                       

**Notes:**

Data for three patients in the vildagliptin cohort and two patients in the comparator cohort are missing. Percentages are calculated based on non-missing values.

**Abbreviations:** AGI, alpha glucosidase inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.
